Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management

Journal of Clinical Virology

Volumn 53, Issue 4, 2012, Pages 354-355

  Garrett, Nigel J ^a   Apea, Vanessa ^a   Nori, Achyuta ^a   Ushiro Lumb, Ines ^b   Oliver, Anthony R ^b   Baily, Guy ^a   Clark, Duncan A ^b  

^a Grahame Hayton Unit   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

HIV; Roche TaqMan version 1.0; TaqMan version 2.0; Viral load blips

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS RESISTANCE;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 84858158855     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.12.024     Document Type: Article

References (8)

1. Oliver A.R., Pereira S.F., Clark D.A. Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay. J Clin Microbiol 2007, 45(11):3616-3619.
2. Pas S., Rossen J.W., Schoener D., Thamke D., Pettersson A., Babiel R., et al. Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA. J Clin Microbiol 2010, 48(4):1195-1200.
3. Smit E., Bhattacharya S., Osman H., Taylor S. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J Acquir Immune Defic Syndr 2009, 51(3):364-365.
4. Damond F., Roquebert B., Bénard A., Collin G., Miceli M., Yéni P., et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol 2007, 45(10):3436-3438.
5. De Bel A., Marissens D., Debaisieux L., Liesnard C., Van den Wijngaert S., Lauwers S., et al. Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche Cobas AmpliPrep/Cobas TaqMan assay. J Clin Microbiol 2010, 48(4):1337-1342.
6. Glaubitz J., Sizmann D., Simon C.O., Hoffmann K.S., Drogan D., Hesse M., et al. Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J Clin Virol 2011, 50(2):119-124.
7. Harrigan R, Sherlock C, Hogg R, Wynhoven B, Chui C, Swenson L, et al. What should be the primary virological endpoint in clinical trials of ARV efficacy? Conference for Retroviruses and Opportunistic Infections 2011, Paper # 661.
8. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2011, vol. 10. Department of Health and Human Services, pp. 1-166. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (accessed 22.09.11).